In Segment A, members will acquire distinct doses and schedules of oral ABBV-744 pill to identify Risk-free dosing routine. Supplemental participants might be enrolled at the recognized monotherapy dosign routine. In Section B, members will acquire oral ruxolitinib and ABBV-744 will probably be provided as "insert-on" therapy. In Phase C, https://abbv-744preclinicalstudie68024.blogunteer.com/31109294/rumored-buzz-on-abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers